Subtotal $0.00
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
Let’s Stay In Touch
- Email:neelam@18.138.41.133
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
Medical and AI strategies & medico-regulatory writing solutions across drug/device development - Product concept to market optimization & beyond...
RXVP
Decision-making is easier when your values are clear.
Prioritizing Patient Safety to Drive Stakeholder Financial Health.
To empower life sciences companies with strategic drug development & life-cycle management solutions that are actionable, ensure patient safety, and enhance commercial success.
To become a trusted advisor that empowers life science companies to achieve breakthrough results.
Decision-making is easier when your values are clear.
Prioritizing Patient Safety to Drive Stakeholder Financial Health.
To empower life sciences companies with strategic drug development & life-cycle management solutions that are actionable, ensure patient safety, and enhance commercial success.
To become a trusted advisor that empowers life science companies to achieve breakthrough results.
CEO & Founder
MBBS, PhD (Pharmaceutical Medicine)
Certified Independent Director – IICA
Corporate Governance – The Wharton School
Founder & CEODr Neelam Kaushal is an MBBS physician with a Ph.D. in Pharmaceutical Medicine, a trained physician-research, an ex-Sun Pharma leader (May 2007–Dec 2024), a certified Independent Director (IICA & The Wharton School), and currently founder of RXVP Pharma Consulting.With over 20 years in global drug development, drug lifecycle management, medico-regulatory strategy in pharma, and healthcare, she is actively building expertise in aligning AI and ESG within the pharmaceutical value chain across its 3Ds - Discover, Develop, and Deliver.She had held pivotal roles in the leading pharmaceutical company (Sun Pharma) for close to 2 decades and has been instrumental in the successful development, global submissions, approvals and commercialization of numerous medical products across globe.
Our Services
Strategic insights at every stage of drug/device development, even if formal documentation is not required at the moment.
RXVP facilitates KOL/physician discussions, regulatory agency engagement, medical due diligence, and portfolio assessments.
Comprehensive medical documentation support across submission, regulatory review, and commercialization & recall stages.
We do not represent any one tool or vendor; our focus is on aligning the right AI solution with the right business problem in the right way.
Proven track record in leading cross-functional teams to achieve regulatory approvals and market success.
Expertise in devising and implementing strategies that align with evolving industry trends and regulatory frameworks.
Active member of the Institute of Directors India, reflecting a commitment to excellence and corporate governance.
RXVP Pharma Consulting partners with global pharma organizations to streamline their product journeys from proof of concept and pre-clinical research to regulatory filings, approvals, market launches, and post-marketing safety and beyond, and act as an AI strategy and implementation advisor.
Satisfied Patients
Professional Doctors
Operations Successful
National Awards Win
Faqs
TESTIMONIALS
“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”
“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”
“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”
“Objectively deploy open-source web-readiness impactful bandwidth. Compellingly coordinate business deliverables rather equity invested technologies. Phosfluorescently reinvent maintainable.”
Our Blog Our Posts
